

# Carlo Colosimo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3456623/publications.pdf>

Version: 2024-02-01

173  
papers

9,768  
citations

57758

44  
h-index

39675

94  
g-index

181  
all docs

181  
docs citations

181  
times ranked

8605  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diabetes mellitus and Parkinson's disease: dangerous liaisons between insulin and dopamine. <i>Neural Regeneration Research</i> , 2022, 17, 523.	3.0	21
2	Lewy body disease or diseases with Lewy bodies?. <i>Npj Parkinson's Disease</i> , 2022, 8, 3.	5.3	26
3	Movement Disorders in Oncology: From Clinical Features to Biomarkers. <i>Biomedicines</i> , 2022, 10, 26.	3.2	5
4	Parkinson's disease advanced therapies - A systematic review: More unanswered questions than guidance. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 132-139.	2.2	26
5	Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 146-149.	2.2	7
6	Subacute axial parkinsonism associated with anti-Ri antibodies. <i>Neurological Sciences</i> , 2021, 42, 1155-1156.	1.9	4
7	The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 448-454.	3.6	16
8	Device-aided therapies for advanced Parkinson disease: insights from an international survey. <i>Neurological Sciences</i> , 2021, 42, 2961-2964.	1.9	7
9	Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. <i>Journal of Neural Transmission</i> , 2021, 128, 321-335.	2.8	37
10	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 182-192.	10.2	74
11	Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 695-705.	2.4	8
12	Lockdown effects on Parkinson's disease during COVID-19 pandemic: a pilot study. <i>Acta Neurologica Belgica</i> , 2021, 121, 1191-1198.	1.1	11
13	Early recognition and diagnosis of multiple system atrophy: best practice and emerging concepts. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 993-1004.	2.8	6
14	A Modified Progressive Supranuclear Palsy Rating Scale. <i>Movement Disorders</i> , 2021, 36, 1203-1215.	3.9	13
15	Alprazolam for essential tremor. <i>The Cochrane Library</i> , 2020, 2020, CD009681.	2.8	3
16	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4-Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	3.9	37
17	Diagnosis and Differential Diagnosis of Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 13-24.	2.6	15
18	Neurological research & training after the easing of lockdown in countries impacted by COVID-19. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117105.	0.6	3

#	ARTICLE	IF	CITATIONS
19	The "egunslinger" sign in progressive supranuclear palsy " Richardson variant. Journal of the Neurological Sciences, 2020, 418, 117108.	0.6	2
20	Botulinum Neurotoxin-A Injection in Adult Cervical Dystonia and Spastic Paresis: Results From the INPUT (INjection Practice, Usage and Training) Survey. Frontiers in Neurology, 2020, 11, 570671.	2.4	4
21	Letter to the editor: "COVID-19 does not reduce stroke-related emergencies" Acta Neurologica Belgica, 2020, 120, 1259-1260.	1.1	5
22	Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: Findings from a prospective, observational study. Journal of the Neurological Sciences, 2020, 416, 117015.	0.6	11
23	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. Movement Disorders Clinical Practice, 2020, 7, 750-762.	1.5	31
24	Prescription of Anticholinergics in Tardive Syndromes: A "Dual Center" Survey among Psychiatrists. Parkinson's Disease, 2020, 2020, 1-4.	1.1	0
25	The Progressive Supranuclear Palsy Clinical Deficits Scale. Movement Disorders, 2020, 35, 650-661.	3.9	31
26	Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders. Movement Disorders Clinical Practice, 2020, 7, 357-360.	1.5	37
27	Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders. Movement Disorders, 2020, 35, 711-715.	3.9	134
28	The long-term effect of continuous subcutaneous apomorphine infusions on camptocormia in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 75, 14-16.	2.2	3
29	Dystonia in atypical parkinsonian disorders. Parkinsonism and Related Disorders, 2019, 66, 25-33.	2.2	25
30	Management of Spastic Paresis and Cervical Dystonia: Access to Therapeutic Innovations Through an International Program of Practical Courses. Clinical Therapeutics, 2019, 41, 2321-2330.e4.	2.5	5
31	Urinary retention discriminates multiple system atrophy from Parkinson's disease. Movement Disorders, 2019, 34, 1926-1928.	3.9	19
32	How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study. Journal of Neurology, 2019, 266, 3038-3046.	3.6	21
33	Paraneoplastic movement disorders: phenomenology, diagnosis, and treatment. European Journal of Internal Medicine, 2019, 67, 14-23.	2.2	11
34	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	3.9	93
35	Disease-modifying therapies for tauopathies: agents in the pipeline. Expert Review of Neurotherapeutics, 2019, 19, 397-408.	2.8	15
36	Early distinction of Parkinson variant multiple system atrophy from Parkinson's disease. Movement Disorders, 2019, 34, 440-441.	3.9	21

#	ARTICLE	IF	CITATIONS
37	Red flags phenotyping: A systematic review on clinical features in atypical parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2019, 59, 82-92.	2.2	22
38	Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. <i>Journal of Neurology</i> , 2018, 265, 856-862.	3.6	51
39	INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin. <i>Journal of Neurology</i> , 2018, 265, 402-409.	3.6	15
40	The rise and fall of impulse control behavior disorders. <i>Parkinsonism and Related Disorders</i> , 2018, 46, S24-S29.	2.2	34
41	Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease. <i>Frontiers in Neurology</i> , 2018, 9, 156.	2.4	136
42	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 33-40.	2.2	17
43	Systematic review of severity scales and screening instruments for tics: Critique and recommendations. <i>Movement Disorders</i> , 2017, 32, 467-473.	3.9	92
44	Hyperkinetic Movement Disorder Emergencies. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 6.	4.2	19
45	Topiramate for essential tremor. <i>The Cochrane Library</i> , 2017, 2017, CD009683.	2.8	7
46	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	3.9	121
47	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. <i>Movement Disorders</i> , 2017, 32, 955-971.	3.9	179
48	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	3.9	1,402
49	Systematic analysis of botulinum neurotoxin type A immunogenicity in clinical studies. <i>Basal Ganglia</i> , 2017, 9, 12-17.	0.3	19
50	Movement disorders and cerebrovascular diseases: from pathophysiology to treatment. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 509-519.	2.8	11
51	Historical note: The first German description of writing tremor in the 19th century. <i>Basal Ganglia</i> , 2017, 10, 12-13.	0.3	0
52	Zonisamide for essential tremor. <i>The Cochrane Library</i> , 2017, 2017, CD009684.	2.8	6
53	Treatment Strategies in Early Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 345-360.	2.0	15
54	Ixcellence Network: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection. <i>Functional Neurology</i> , 2017, 32, 103.	1.3	7

#	ARTICLE	IF	CITATIONS
55	Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease. PLoS ONE, 2016, 11, e0151156.	2.5	100
56	Camptocormia may be myopathic or dystonic. Muscle and Nerve, 2016, 54, 343-343.	2.2	4
57	Plasma Screening for Progranulin Mutations in Patients with Progressive Supranuclear Palsy and Corticobasal Syndromes. Journal of Alzheimer's Disease, 2016, 53, 445-449.	2.6	3
58	Primary motor cortex LTP/LTD-like plasticity in probable corticobasal syndrome. Journal of Neurophysiology, 2016, 115, 717-727.	1.8	14
59	Poster 187 Is There a Correlation Between Tremor and Other Symptoms of Cervical Dystonia? An Analysis of Data from the Ongoing INTEREST IN CD2 Study. PM and R, 2016, 8, S222.	1.6	0
60	Neuroimaging correlates of blinking abnormalities in patients with progressive supranuclear palsy. Movement Disorders, 2016, 31, 138-143.	3.9	13
61	Nonmotor symptoms in Parkinson's disease: are we still waiting for the honeymoon?. European Journal of Neurology, 2016, 23, 1595-1596.	3.3	3
62	Cardiovascular dysfunction in untreated Parkinson's disease: A multi-modality assessment. Journal of the Neurological Sciences, 2016, 370, 251-255.	0.6	43
63	Constipation: an emerging risk factor for Parkinson's disease?. European Journal of Neurology, 2016, 23, 1606-1613.	3.3	68
64	MRI gray and white matter measures in progressive supranuclear palsy and corticobasal syndrome. Journal of Neurology, 2016, 263, 2022-2031.	3.6	18
65	Pregabalin for essential tremor. The Cochrane Library, 2016, 10, CD009682.	2.8	4
66	Supine hypertension in Parkinson's disease and multiple system atrophy. Clinical Autonomic Research, 2016, 26, 97-105.	2.5	87
67	Gray and white matter structural changes in corticobasal syndrome. Neurobiology of Aging, 2016, 37, 82-90.	3.1	28
68	Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis. Neurotoxicity Research, 2016, 29, 105-117.	2.7	79
69	Therapeutic interventions in parkinsonism: Corticobasal degeneration. Parkinsonism and Related Disorders, 2016, 22, S96-S100.	2.2	23
70	How Do I Examine Blepharospasm?. Movement Disorders Clinical Practice, 2015, 2, 449-449.	1.5	3
71	Spread of Muscle Spasms in Hemifacial Spasm. Movement Disorders Clinical Practice, 2015, 2, 53-55.	1.5	7
72	A Case of Atypical Adult-onset Tic Disorder. Neurologist, 2015, 19, 99-100.	0.7	3

#	ARTICLE	IF	CITATIONS
73	Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 111-115.	2.2	26
74	Treatment of camptocormia with botulinum toxin. <i>Toxicon</i> , 2015, 107, 148-153.	1.6	20
75	Psychogenic tremor in Parkinson's disease. <i>Acta Neurologica Belgica</i> , 2015, 115, 829-830.	1.1	6
76	Scales for hyperkinetic disorders: A systematic review. <i>Journal of the Neurological Sciences</i> , 2015, 358, 9-21.	0.6	32
77	Tonic lip deviation as a distinctive form of psychogenic facial dystonia. <i>Journal of the Neurological Sciences</i> , 2015, 358, 486-487.	0.6	4
78	Autonomic failure and reduced survival in multiple system atrophy. <i>Brain</i> , 2015, 138, 3466-3468.	7.6	6
79	Animal Models of Multiple-System Atrophy. , 2015, , 887-904.		0
80	Dyskinesias and motor symptoms onset in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1427-1429.	2.2	7
81	Nocturnal manifestations of atypical and vascular parkinsonism: How do they differ from Parkinson's disease?. <i>Journal of Neural Transmission</i> , 2014, 121, 69-77.	2.8	5
82	Blinking in patients with clinically probable multiple system atrophy. <i>Movement Disorders</i> , 2014, 29, 415-420.	3.9	15
83	Fifty years of progressive supranuclear palsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 938-944.	1.9	43
84	Detecting nocturnal hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support algorithm. <i>Journal of Neurology</i> , 2014, 261, 1291-1299.	3.6	47
85	The role of subcutaneous infusion of apomorphine in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 833-843.	2.8	30
86	Nocturnal Manifestations of Atypical Parkinsonian Disorders. <i>Journal of Parkinson's Disease</i> , 2014, 4, 223-236.	2.8	8
87	Psychiatric disturbances in patients with progressive supranuclear palsy: A case-control study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 965-968.	2.2	23
88	Primary motor cortex long-term plasticity in multiple system atrophy. <i>Movement Disorders</i> , 2014, 29, 97-104.	3.9	28
89	Dyskinesia Rating Scales in Parkinson's Disease. , 2014, , 17-31.		0
90	Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. <i>Journal of Neurology</i> , 2013, 260, 714-740.	3.6	74

#	ARTICLE	IF	CITATIONS
91	The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology</i> , 2013, 12, 264-274.	10.2	426
92	Tremor in primary adult-onset dystonia: prevalence and associated clinical features. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 404-408.	1.9	71
93	Effect of camptocormia on lung volumes in Parkinson's disease. <i>Respiratory Physiology and Neurobiology</i> , 2013, 187, 164-166.	1.6	6
94	Selective impairment of action-verb naming and comprehension in progressive supranuclear palsy. <i>Cortex</i> , 2013, 49, 948-960.	2.4	50
95	Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey. <i>Functional Neurology</i> , 2013, 28, 253-8.	1.3	14
96	Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 76-82.	1.9	82
97	Abnormal Cortical Synaptic Plasticity in Primary Motor Area in Progressive Supranuclear Palsy. <i>Cerebral Cortex</i> , 2012, 22, 693-700.	2.9	49
98	A Further Case of Nicotine Sensitivity in Multiple System Atrophy. <i>Clinical Neuropharmacology</i> , 2012, 35, 51-52.	0.7	5
99	The Unified Multiple System Atrophy Rating Scale: Intrarater reliability. <i>Movement Disorders</i> , 2012, 27, 1683-1685.	3.9	18
100	The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. <i>Journal of Neurology</i> , 2012, 259, 2621-2631.	3.6	188
101	Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 871-875.	2.2	23
102	Efficacy and Safety of Long-term Botulinum Toxin Treatment in Craniocervical Dystonia: A Systematic Review. <i>Neurotoxicity Research</i> , 2012, 22, 265-273.	2.7	61
103	Thrombolysis in hemiballism: is it a rational choice?. <i>Internal and Emergency Medicine</i> , 2012, 7, 125-126.	2.0	1
104	Deep Brain Stimulation for Movement Disorders – A History of Success and Challenges to Conquer. <i>Frontiers in Integrative Neuroscience</i> , 2012, 6, 6.	2.1	5
105	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. <i>Neurological Sciences</i> , 2012, 33, 585-593.	1.9	18
106	A Stiff and Jerky Person: How Useful Is a DAT Scan in the Differential Diagnosis?. , 2012, , .		0
107	Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia. <i>Functional Neurology</i> , 2012, 27, 225-30.	1.3	14
108	Nonmotor presentations of multiple system atrophy. <i>Nature Reviews Neurology</i> , 2011, 7, 295-298.	10.1	43

#	ARTICLE	IF	CITATIONS
109	Clinical Phenomenology of Dystonia. <i>International Review of Neurobiology</i> , 2011, 98, 509-524.	2.0	14
110	The differential diagnosis of parkinsonism: A clinical approach. , 2011, , 126-141.		0
111	Excessive Daytime Sleepiness in Multiple System Atrophy (SLEEMSA Study). <i>Archives of Neurology</i> , 2011, 68, 223-30.	4.5	83
112	Somatosensory temporal discrimination tested in patients receiving botulinum toxin injection for cervical dystonia. <i>Movement Disorders</i> , 2011, 26, 742-746.	3.9	40
113	Psychiatric disorders in adult onset focal dystonia. <i>Movement Disorders</i> , 2011, 26, 1572-1572.	3.9	4
114	Nonmotor symptoms in adult-onset focal dystonia: Psychiatric abnormalities. <i>Movement Disorders</i> , 2011, 26, 1764-1765.	3.9	10
115	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. <i>Journal of Neurology</i> , 2010, 257, 5-14.	3.6	140
116	Levodopa: back to the future. <i>Journal of Neurology</i> , 2010, 257, 247-248.	3.6	40
117	Dopaminergic system in peripheral blood mononuclear cells in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 125-126.	3.9	6
118	Psychiatric disorders in adult-onset focal dystonia: A case-control study. <i>Movement Disorders</i> , 2010, 25, 459-465.	3.9	156
119	An early image of hemifacial spasm: Édouard Brissaud contribution. <i>Movement Disorders</i> , 2010, 25, 531-533.	3.9	9
120	Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2010, 25, 1131-1142.	3.9	90
121	Bladder symptoms assessed with overactive bladder questionnaire in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1203-1209.	3.9	28
122	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , 2010, 25, 2604-2612.	3.9	205
123	No association between essential tremor and migraine: A case-control study. <i>Cephalalgia</i> , 2010, 30, 686-689.	3.9	10
124	Secondary parkinsonism due to arachnoid cyst of the frontal lobe. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 400-400.	1.9	9
125	â€˜Abnormalâ€™ DaTSCAN in a case of unilateral hand tremor associated with caudate infarct. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 356-357.	2.2	7
126	Injection of the iliopsoas muscle with botulinum toxin in camptocormia. <i>Movement Disorders</i> , 2009, 24, 316-317.	3.9	32



#	ARTICLE	IF	CITATIONS
127	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1641-1649.	3.9	1,171
128	Onset and spread of dyskinesias and motor symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2091-2096.	3.9	26
129	Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy. <i>Journal of Neural Transmission</i> , 2009, 116, 161-165.	2.8	13
130	Cranial movement disorders: clinical features, pathophysiology, differential diagnosis and treatment. <i>Nature Clinical Practice Neurology</i> , 2009, 5, 93-105.	2.5	40
131	The PRIAMO study: background, methods and recruitment. <i>Neurological Sciences</i> , 2008, 29, 61-65.	1.9	28
132	Mirror movements in patients with Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 253-258.	3.9	40
133	Red flags for multiple system atrophy. <i>Movement Disorders</i> , 2008, 23, 1093-1099.	3.9	215
134	Clinical differential diagnosis of parkinsonism. <i>Future Neurology</i> , 2008, 3, 287-298.	0.5	1
135	Voluntary, spontaneous and reflex blinking in patients with clinically probable progressive supranuclear palsy. <i>Brain</i> , 2008, 132, 502-510.	7.6	64
136	Multiple System Atrophy. , 2007, , 83-93.		2
137	Investigational drugs. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 84, 137-150.	1.8	1
138	Health-related quality of life in multiple system atrophy. <i>Movement Disorders</i> , 2006, 21, 809-815.	3.9	102
139	Which Model of Stroke Unit Is Better for Stroke Patient Management?. <i>Clinical and Experimental Hypertension</i> , 2006, 28, 377-382.	1.3	4
140	Primary vs Postparalytic Hemifacial Spasm—Reply. <i>Archives of Neurology</i> , 2006, 63, 1204.	4.5	1
141	A Comparative Study of Primary and Secondary Hemifacial Spasm. <i>Archives of Neurology</i> , 2006, 63, 441.	4.5	106
142	Head trauma in primary cranial dystonias: a multicentre case-control study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 260-263.	1.9	28
143	Drug Insight: new drugs in development for Parkinson's disease. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 600-610.	2.5	14
144	Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 77-81.	3.9	132

#	ARTICLE	IF	CITATIONS
145	Caseâ€“control study of multiple system atrophy. <i>Movement Disorders</i> , 2005, 20, 158-163.	3.9	65
146	Reply: Lack of association between progressive supranuclear palsy and arterial hypertension: A clinicopathological study. <i>Movement Disorders</i> , 2005, 20, 1086-1087.	3.9	0
147	Clinical Spectrum and Pathological Features of Multiple System Atrophy. , 2005, , 541-570.		2
148	Multiple system atrophy. , 2005, , 623-662.		2
149	Diffusion tensor imaging in primary cervical dystonia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1591-1593.	1.9	89
150	Multiple system atrophy. <i>Lancet Neurology, The</i> , 2004, 3, 93-103.	10.2	443
151	Cerebrospinal fluid analysis for Whipple's disease in patients with progressive supranuclear palsy. <i>Movement Disorders</i> , 2004, 19, 220-222.	3.9	4
152	Accuracy of clinical diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2004, 19, 181-189.	3.9	190
153	Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). <i>Movement Disorders</i> , 2004, 19, 1391-1402.	3.9	481
154	Lack of association between progressive supranuclear palsy and arterial hypertension: A clinicopathological study. <i>Movement Disorders</i> , 2003, 18, 694-697.	3.9	21
155	Noradrenergic Drugs for Levodopa-Induced Dyskinesia. <i>Clinical Neuropharmacology</i> , 2003, 26, 299-305.	0.7	25
156	The symptomatic treatment of multiple system atrophy. <i>European Journal of Neurology</i> , 2002, 9, 195-199.	3.3	32
157	Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. <i>Movement Disorders</i> , 2001, 16, 197-201.	3.9	111
158	Acute Challenge with Apomorphine and Levodopa in Parkinsonism. <i>European Neurology</i> , 2000, 43, 95-101.	1.4	59
159	Motor fluctuations in Parkinson's disease: pathophysiology and treatment. <i>European Journal of Neurology</i> , 1999, 6, 1-21.	3.3	80
160	The rise and fall of tolcapone. <i>Journal of Neurology</i> , 1999, 246, 880-882.	3.6	40
161	The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. <i>Neuroscience Letters</i> , 1999, 274, 61-65.	2.1	26
162	Reduced dopamine in peripheral blood lymphocytes in Parkinson's disease. <i>NeuroReport</i> , 1999, 10, 2907-2910.	1.2	58

#	ARTICLE	IF	CITATIONS
163	Pisa syndrome in a patient with multiple system atrophy. <i>Movement Disorders</i> , 1998, 13, 607-609.	3.9	57
164	Sleep benefit in parkinson's disease. <i>Movement Disorders</i> , 1997, 12, 506-508.	3.9	77
165	Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study. <i>Journal of Neurology</i> , 1996, 243, 422-425.	3.6	44
166	Clozapine in Huntington's disease. <i>Neurology</i> , 1995, 45, 1023-1023.	1.1	20
167	Clinical Usefulness of Apomorphine in Movement Disorders. <i>Clinical Neuropharmacology</i> , 1994, 17, 243-259.	0.7	70
168	Unsuspected, surreptitious drug-induced parkinsonism. <i>Neurology</i> , 1992, 42, 459-459.	1.1	5
169	Treatment of blepharospasm. , 0, , 49-52.		2
170	Corticobasal degeneration. , 0, , 75-98.		1
171	Treatment of blepharospasm. , 0, , 60-63.		0
172	Botulinum Toxin Therapy for Cranial Dystonia. , 0, , 167-171.		0
173	Multiple system atrophy. , 0, , 27-57.		0